They added they hope the simpler access to Zepbound will discourage people from using untested, knock-off prescription drugs to take care of obesity.When ACP values initiatives to get rid of obstacles to care, which is one of Lilly’s mentioned ambitions, “they need to not devalue the verified benefits of the patient-health practitioner partners